Sarcopenia Is Associated with Reduced Overall and Disease-Free Survival in Patients Undergoing Esophagectomy for Locally Advanced Esophageal Cancer

15185 Background: The prognosis of patients with locally advanced esophageal cancer is poor. TMT for locally advanced esophageal cancer is being utilized with increasing frequency. In this study, we investigate the prognostic factors influencing survival in patients with locally advanced esophageal cancer following TMT. Methods: The study included 22 patients with esophageal carcinoma treated between January 2003 and December 2005 at Shaukat Khanum Memorial Hospital and Research Centre. Median age was 49 years (range 26 - 68). There were 15 (68%) males and 7 (32%) females. All patients had EGD with biopsy and CT chest. Twelve (54.5%) had squamous cell carcinoma and 10 (45.5%) patients had adenocarcinoma. Five patients (23%) had tumour in the middle third and 17 (77%) had lower/gastroesophageal lesions. Preoperative radiation consisted of 50.4 Gy / 28 fractions with concomitant chemotherapy day 1 and 29 (Cisplatin 75 mg/m2 day 1 and infusional 5FU 1000 mg/m2 day 1–5). Esophagectomy was done at 6 - 12 weeks following chemoradiation. The pathologic down-staging was evaluated by the 5-score tumor regression grade (TRG) of Mandard. Results: Post TMT pathologic TNM stage was; Stage 0 in 8 pts (36%), stage II in 5 pts (23%) and stage III in 9 pts (41%). 13 (59%) pts had R0 and 9 (41%) pts had R1 resection. The 4-year disease free survival was 29% with a median survival of 19 months. The number of patients with TRG score 1, 2, 3, 4 and 5 were 7 (32%), 4 (18%), 5 (23%), 2 (9%) and 4 (18%) respectively. Tumor regression grade 1–2 (p=.0016) and negative circumferential margins >2 mm (p=.0019) had a positive influence on DFS. Age (< 50 vs ≥ 50 years), sex, hemoglobin at presentation (≤ 12 vs > 12 gm/dl), tumor site (middle vs lower/GE junction), pathological nodal status (node positive vs node negative) and histological subtype (squamous cell vs adenocarcinoma) did not influence survival (p= 0.92, p= 0.82, p= 0.69, p= 0.79, p= 0.41 and p= 0.32 respectively). Conclusions: TMT results in prolonged disease free survival in patients with complete response or microscopic residual foci (TRG 1–2). Positive or circumferential margins <2mm is associated with poor prognosis. No significant financial relationships to disclose.

Download Full-text

Outcomes associated with T4 esophageal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.4_suppl.130 ◽

2011 ◽

Vol 29 (4_suppl) ◽

pp. 130-130

Author(s):

K. Meredith ◽

J. Weber ◽

R. Shridhar ◽

S. E. Hoffe ◽

K. Almhanna ◽

...

Keyword(s):

Esophageal Cancer ◽

Neoadjuvant Therapy ◽

Locally Advanced ◽

Survival Rates ◽

Disease Free Survival ◽

Pathologic Response ◽

Additional Patient ◽

Free Survival ◽

T4 Esophageal Cancer ◽

Disease Free

130 Background: Esophageal cancer often presents as locally advanced disease with 15% of patients having T4 tumors upon diagnosis. Esophagectomy was often reserved for palliation given the dismal survival rates and high rates of R1/R2 resections. However, neoadjuvant therapy (NT) has the potential to significantly downstage esophageal cancers and thus increase complete resection rates. We report our experience with surgically resected T4 cancers of the esophagus. Methods: Using a comprehensive esophageal cancer database, we identified patients who underwent an esophagectomy for T4 tumors between 1994 and 2008. Neoadjuvant therapy and pathologic response were recorded and denoted as complete (pCR), partial (pPR), and non-response (NR). Clinical and pathologic data were compared using Fisher's exact and chi-square when appropriate while Kaplan Meier estimates were used for survival analysis. Results: We identified 39 patients with T4 tumors who underwent esophagectomy of which 38 (97%) underwent NT. The median age was 61 (31-79) years with a median follow-up of 32 (5-97) months. There were 3 (7.9%) pCR, 17 (44.7%) pPR, and 18 (47.4%) NR. R0 resections were accomplished in 37 (94.9%). Two patients had incomplete resections. One patient had a R2 resection after NT and was deemed as NR. An additional patient had a R1 resection after NT and was a pPR with a residual 0.2 cm tumor on permanent pathology. There were 14 (35.9%) recurrences with a median time to recurrence of 19.5 (4-71) months. Complete pathologic response represented 1 (7.1%), whereas pPR and NR represented 6 (42.9%), and 7 (50%) respectively of all recurrences. The overall and disease free survival for all patients with T4 tumors was 28% and 34% respectively. Patients achieving a pCR had a 5-year overall and disease free survival of (43% and 47%), compared to pPR (30% and 21%) while there were no 5-year survivors in the NR cohort. Conclusions: T4 esophageal cancer often portends a dismal prognosis even after surgical resection. Historical incomplete resections and dismal survival rates often make surgery palliative rather then curative. However, we have demonstrated that neoadjuvant therapy and down staging of T4 tumors leads to increased R0 resections and improvements in overall and disease free survival. No significant financial relationships to disclose.

Download Full-text

36 ANALYZING WHETHER PET SCAN PARAMETERS PREDICT FOR PROGRESSION FREE SURVIVAL IN LOCALLY ADVANCED ESOPHAGEAL CANCER

Radiotherapy and Oncology ◽

10.1016/s0167-8140(12)72423-4 ◽

2009 ◽

Vol 92 ◽

pp. S12

Author(s):

D. Schellenberg ◽

S. Ghambir ◽

E. Graves ◽

D. Wilson

Keyword(s):

Esophageal Cancer ◽

Locally Advanced ◽

Progression Free Survival ◽

Pet Scan ◽

Advanced Esophageal Cancer ◽

Free Survival ◽

Locally Advanced Esophageal Cancer

Download Full-text

18F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer.

10.21203/rs.2.18946/v1 ◽

2019 ◽

Author(s):

Styliani Mantziari ◽

Anastasia Pomoni ◽

John O Prior ◽

Michael Winiker ◽

Pierre Allemann ◽

...

Keyword(s):

Esophageal Cancer ◽

Fdg Pet ◽

Tumor Recurrence ◽

Locally Advanced ◽

Disease Free Survival ◽

Free Survival ◽

Pet Ct ◽

Early Tumor ◽

Fdg Pet Ct ◽

Disease Free

Abstract Background Although 18 F- FDG PET/CT is validated in baseline workup of esophageal cancer to detect distant metastases, it remains underused in assessing local staging and biology of the primary tumor. This study aimed to evaluate the association between 18 F- FDG PET/CT-derived parameters of esophageal cancer, and its clinico-pathological features and prognosis.Methods All patients (n=86) with esophageal adenocarcinoma or squamous cell cancer operated between 2005-2014 were analyzed. Linear regression was used to identify clinico-pathologic features of esophageal cancer associated with the tumor’s maximal Standardized Uptake Value (SUV max ), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). ROC curve analysis was performed to precise the optimal cutoff of each variable associated with a locally advanced (cT3/4) status, long-term survival and recurrence. Kaplan Meier curves and Cox regression were used for survival analyses.Results High baseline SUV max was associated with cT3/4 status and middle-third tumor location, TLG with a cT3/4 and cN+ status, whereas MTV only with active smoking. A cT3/4 status was significantly predicted by a SUV max >8.25g/mL (p<0.001), TLG>41.7 (p<0.001) and MTV>10.70 cm 3 (p<0.01) whereas a SUV max > 12.7 g/mL was associated with an early tumor recurrence and a poor disease-free survival (median 13 versus 56 months, p=0.030), particularly in squamous cell cancer.Conclusions Baseline 18 F- FDG PET/CT has a high predictive value of preoperative cT stage, as its parameters SUV max , TLG and MTV can predict a locally advanced tumor with high accuracy. A SUV max > 12.7 g/mL may herald early tumor recurrence and poor disease-free survival.

Download Full-text

179 FEASIBILITY AND ONCOLOGICAL OUTCOME OF CHEMORADIATION WITH INTENSIFIED IMRT IN LOCALLY ADVANCED ESOPHAGEAL CANCER

Diseases of the Esophagus ◽

10.1093/dote/doaa087.34 ◽

2020 ◽

Vol 33 (Supplement_1) ◽

Author(s):

R Innocente ◽

F Navarria ◽

R Petri ◽

E Palazzari ◽

M Gigante ◽

...

Keyword(s):

Esophageal Cancer ◽

Tumor Volume ◽

Locally Advanced ◽

Progression Free Survival ◽

Oncological Outcome ◽

Advanced Esophageal Cancer ◽

Free Survival ◽

Ecog Ps ◽

Locally Advanced Esophageal Cancer

Abstract To assess safety, feasibility and efficacy of an intensified preoperative IMRT and concomitant carboplatin and paclitaxel-based chemotherapy (Carbo/Tax CT) in patients (pts) with locally advanced esophageal cancer (LAEC) treated at our Institution. Methods a retrospective analysis of toxicity (CTCAE 4.03), progression free survival (PFS) and overall survival (OS) of pts affected by LAEC, treated with preoperative intensified radiotherapy (IMRT) and weekly concurrent carboplatin and paclitaxel-based chemotherapy (CT) according to the CROSS trial, between February 2016 and October 2019, at the Centro di Riferimento Oncologico, Aviano (CRO). Results Sixty-nine consecutive pts, 57(82.6%) males, were treated. The median age was 69 yrs (38–85), the ECOG PS 0–2. All pts underwent concurrent chemoradiotherapy, IMRT technique, 45 Gy/25 to PTV1 (primary tumor volume + regional nodes), a simultaneous boost from 52.5Gy to 54Gy to PTV2 (gross tumor volume) and weekly concurrent carboplatin (AUC2) and paclitaxel (50 mg/m2). Induction CT was administered to 17 pts. All pts completed RT with median 4 (1–5) CT cycles. Median follow-up was 8 months (4–17); 2-yr PFS and OS were 49.0% and 80.3%, respectively. At 2 yrs, local recurrence rate was 8.4% (CI 95%: 2.6%–18.8%). Conclusion Preoperative intensified IMRT with concomitant Carbo/Tax CT in pts with LAEC appears safe and feasible with promising oncological outcome and needs to be confirmed in a larger series of pts.

Download Full-text

18FDG PET/CT-derived parameters successfully predict clinical stage and prognosis of esophageal cancer.

10.21203/rs.2.10238/v1 ◽

2019 ◽

Author(s):

Styliani Mantziari ◽

Anastasia Pomoni ◽

John Prior ◽

Michael Winiker ◽

Pierre Allemann ◽

...

Keyword(s):

Esophageal Cancer ◽

Squamous Cell Cancer ◽

Cell Cancer ◽

Locally Advanced ◽

Disease Free Survival ◽

Free Survival ◽

18Fdg Pet ◽

Pet Ct ◽

Early Tumor ◽

Disease Free

Abstract Background Although 18FDG PET/CT is validated in baseline workup of esophageal cancer to detect distant metastases, it remains underused in assessing local staging and biology of the primary tumor. This study aimed to evaluate the association between 18FDG PET/CT-derived parameters of esophageal cancer, and its clinico-pathological features and prognosis. Methods All patients with esophageal adenocarcinoma or squamous cell cancer of operated between 2005-2014 were analyzed. Linear regression was used to identify clinico-pathologic features of esophageal cancer associated with the tumor’s maximal Standardized Uptake Value (SUVmax), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). ROC curve analysis was performed to precise the optimal cutoff of each variable associated with a locally advanced (cT3/4) status, long-term survival and recurrence. Kaplan Meier curves and Cox regression were used for survival analyses. Results High baseline SUVmax was associated with cT3/4 status and middle-third tumor location, TLG with a cT3/4 and cN+ status, whereas MTV only with active smoking. A cT3/4 status was significantly predicted by a SUVmax >8.25g/mL (p<0.001), TLG>41.7 (p<0.001) and MTV>10.70 cm3 (p<0.01) whereas a SUVmax > 12.7 g/mL was associated with an early tumor recurrence and a poor disease-free survival (median 13 versus 56 months, p=0.030), particularly in squamous cell cancer. Conclusions Baseline 18FDG PET/CT has a high predictive value of preoperative cT stage, as its parameters SUVmax, TLG and MTV can predict a locally advanced tumor with high accuracy. A SUVmax > 12.7 g/mL may herald early tumor recurrence and poor disease-free survival.

Download Full-text

18 F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer.

10.21203/rs.2.18946/v2 ◽

2019 ◽

Author(s):

Styliani Mantziari ◽

Anastasia Pomoni ◽

John O Prior ◽

Michael Winiker ◽

Pierre Allemann ◽

...

Keyword(s):

Esophageal Cancer ◽

Fdg Pet ◽

Tumor Recurrence ◽

Locally Advanced ◽

Disease Free Survival ◽

Free Survival ◽

Pet Ct ◽

Early Tumor ◽

Fdg Pet Ct ◽

Disease Free

Abstract Background Although 18 F- FDG PET/CT is validated in baseline workup of esophageal cancer to detect distant metastases, it remains underused in assessing local staging and biology of the primary tumor. This study aimed to evaluate the association between 18 F- FDG PET/CT-derived parameters of esophageal cancer, and its clinico-pathological features and prognosis.Methods All patients (n=86) with esophageal adenocarcinoma or squamous cell cancer operated between 2005-2014 were analyzed. Linear regression was used to identify clinico-pathologic features of esophageal cancer associated with the tumor’s maximal Standardized Uptake Value (SUV max ), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). ROC curve analysis was performed to precise the optimal cutoff of each variable associated with a locally advanced (cT3/4) status, long-term survival and recurrence. Kaplan Meier curves and Cox regression were used for survival analyses.Results High baseline SUV max was associated with cT3/4 status and middle-third tumor location, TLG with a cT3/4 and cN+ status, whereas MTV only with active smoking. A cT3/4 status was significantly predicted by a SUV max >8.25g/mL (p<0.001), TLG>41.7 (p<0.001) and MTV>10.70 cm 3 (p<0.01) whereas a SUV max > 12.7 g/mL was associated with an early tumor recurrence and a poor disease-free survival (median 13 versus 56 months, p=0.030), particularly in squamous cell cancer.Conclusions Baseline 18 F- FDG PET/CT has a high predictive value of preoperative cT stage, as its parameters SUV max , TLG and MTV can predict a locally advanced tumor with high accuracy. A SUV max > 12.7 g/mL may herald early tumor recurrence and poor disease-free survival.

Download Full-text